Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study

Mendel Fux, Jonathan Benjamin, R. H. Belmaker

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Abstract

Current serotonin reuptake inhibitor (SRI) treatments for obsessive-compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.

Original languageEnglish
Pages (from-to)193-195
Number of pages3
JournalInternational Journal of Neuropsychopharmacology
Volume2
Issue number3
DOIs
StatePublished - 1 Jan 1999

Keywords

  • Augmentation
  • Inositol
  • Obsessive-compulsive disorder
  • Serotonin reuptake inhibitors.

Fingerprint

Dive into the research topics of 'Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study'. Together they form a unique fingerprint.

Cite this